{
    "title": "Melittin vs HIV / Cancer",
    "inventor_name": "Joshua L. Hood, MD, PhD (et al.)",
    "publication_year": 2013,
    "device_name": "Melittin-loaded nanoparticle gel",
    "goal": "Prevent HIV infection and provide contraceptive protection using a vaginal gel that kills virus and sperm without harming host cells.",
    "problem_addressed": "Sexually transmitted HIV and lack of safe, user-controlled contraceptive methods.",
    "concept_summary": "Perfluorocarbon nanoparticles are coated with a lipid/surfactant layer and loaded with the membrane-disrupting peptide melittin. The particles are sized (~=250 nm) so that they can enter the viral envelope (~=100 nm) but are excluded from larger human cells. When the nanoparticle contacts HIV, melittin inserts into the viral membrane, forming pores that rupture the envelope and inactivate the virus. Protective \"bumpers\" on the particle surface prevent interaction with normal cells. The same platform can be targeted to sperm using antibodies or aptamers for contraceptive use.",
    "detailed_description": "The invention uses perfluorocarbon-based nanoparticles (PFC-NP) originally developed as artificial blood products. The core is a perfluorocarbon fluid; the surface is a lipid/surfactant bilayer that can incorporate cationic, anionic, or amphipathic peptides. Melittin (or analogues) is embedded in the coating, where it remains inactive until the particle fuses with a target membrane. For HIV, the particle size is larger than the virus, allowing the virus to fit between protective \"bumpers\" and contact the melittin-laden surface, leading to pore formation and loss of viral RNA. For sperm, targeting ligands (e.g., antibodies against I+/-vI23 integrin, SPAM1, or progesterone) are attached to the particle to promote fusion with the sperm membrane, where melittin then creates pores that impair motility or viability. In vitro studies showed ( HIV infectivity, no cytotoxicity to vaginal epithelial cells, and selective effects on sperm when targeted. The formulation can be incorporated into a vaginal gel or administered intravenously for systemic therapy.",
    "principles": [
        "Membrane disruption by pore-forming peptide (melittin)",
        "Size-based exclusion of host cells",
        "Targeted delivery via antibodies/aptamers",
        "Passive fusion driven by lipid membrane tension"
    ],
    "scientific_domains": [
        "Virology",
        "Nanomedicine",
        "Biochemistry",
        "Pharmaceutical Sciences"
    ],
    "mechanisms_of_action": [
        "Melittin inserts into lipid bilayers forming pores",
        "Nanoparticle size prevents interaction with larger mammalian cells",
        "Targeting ligands bind specific receptors on sperm or virus",
        "Fusion of nanoparticle with target membrane releases melittin locally"
    ],
    "materials": [
        "Perfluorocarbon fluid (core)",
        "Lipid/surfactant coating",
        "Melittin peptide (or analogues)",
        "Targeting antibodies / aptamers / peptidomimetics",
        "Progesterone (optional chemoattractant)"
    ],
    "energy_sources": [],
    "inputs": [
        "Melittin peptide",
        "Perfluorocarbon fluid",
        "Lipids / surfactants",
        "Targeting ligands (antibodies, aptamers)",
        "Formulation buffer / gel base"
    ],
    "outputs": [
        "Vaginal gel containing melittin-loaded nanoparticles",
        "Nanoparticle suspension for potential intravenous use"
    ],
    "claimed_performance": "In vitro HIV infectivity reduced to background levels; no measurable toxicity to vaginal epithelial cells; targeted sperm motility reduction while sparing non-targeted cells; particles stable in vaginal environment and remain localized.",
    "experimental_evidence": "Figures in the patent show (1) viability of vaginal epithelium with free vs. nanoparticle-bound melittin, (2) inhibition of HIV infection in vitro, (3) loss of infectivity for HIV-p120 and HIV-p134 strains, (4) targeting efficiency of CD4-coupled particles, (5) effects on sperm motility and viability with and (6) successful targeting using SPAM1 antibody.",
    "replication_status": "Published peer-reviewed article in Antiviral Therapy (Vol 19, 2013) and US Patent US2012100186; no independent replication reported.",
    "keywords": [
        "melittin",
        "nanoparticle",
        "HIV",
        "vaginal gel",
        "contraception",
        "perfluorocarbon",
        "membrane-disrupting peptide"
    ],
    "related_technologies": [
        "Liposome drug delivery",
        "Antiviral microbicides",
        "Targeted nanocarriers"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.7,
    "fringe_score": 0.2,
    "evidence_strength": 0.6,
    "risk_score": 0.3,
    "trl_estimate": 4,
    "source_urls": [
        "http://news.wustl.edu/news/Pages/25061.aspx",
        "https://patents.google.com/patent/US2012100186"
    ],
    "organizations": [
        "Washington University School of Medicine",
        "United States Patent and Trademark Office"
    ],
    "applications": [
        "HIV prevention (microbicide)",
        "Female contraception",
        "Cancer therapy (tumor cell killing via melittin)"
    ],
    "limitations": [
        "Data limited to in vitro experiments",
        "Potential off-target membrane damage if melittin is released uncontrolled",
        "Formulation stability and retention in vaginal mucosa not fully characterized",
        "Regulatory approval pathway not yet demonstrated"
    ],
    "open_questions": [
        "Efficacy and safety in animal models and human clinical trials",
        "Long-term effects on vaginal microbiome and mucosal immunity",
        "Optimal dosing and release kinetics",
        "Scalability of manufacturing perfluorocarbon nanoparticles"
    ],
    "red_flags": [
        "Membrane-disrupting peptide could damage non-target cells at high concentrations",
        "Need for rigorous toxicology testing before clinical use"
    ],
    "evidence_quotes": [
        "Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed.",
        "Melittin on the nanoparticles fuses with the viral envelope... forming little pore-like attack complexes and ruptures the envelope.",
        "The nanoparticles are typically perfluorocarbon nanoparticles (PFC-NP) and carry a potent toxin in the form of a membrane-integrating peptide that results in the formation of pores in the sperm or virus when these are fused to the nanoparticles.",
        "Figure 2 shows the results of an in vitro experiment whereby HIV infection is prevented by melittin-containing nanoparticles of the invention."
    ],
    "category": "Nanotechnology"
}